DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...

Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...

Introduction We aimed to establish the clinical characteristics of children and young people (CAYP) currently receiving deep brain stimulation (DBS) therapy for the management of movement disorders in ...

Others could just as easily be on the 2025 list. Medtronic’s Activa Tremor Control Therapy was featured in the 2000 issue as one of the first forays into deep brain stimulation as a treatment for ...

Techsomed Ltd., an Israel-based developer of medical artificial intelligence–powered software for image-guided therapy, a ...

The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin ...

Medtronic (NYSE: MDT) announced today that it received new labeling approval from the FDA for its Endurant stent graft system.

While there is no cure for Parkinson’s disease, there’s now a better way to control its involuntary muscle movements. In February, the FDA approved Medtronic’s BrainSense adaptive deep brain ...

In September 2025, Medtronic announced it had received FDA approval and launched the Altaviva device, a minimally invasive implant designed to treat urge urinary incontinence by delivering automatic ...

Subthalamic deep brain stimulation is an effective long-term therapy for Parkinson disease, according to a recent study.

Lab-grown seafood, a new treatment for Parkinson's disease and a kid-safe power saw are among the genius ideas from UC ...